Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy for tough myeloma cases shows early promise but study halted

NCT ID NCT03031730

First seen Feb 18, 2026 · Last updated May 24, 2026 · Updated 8 times

Summary

This early-phase study tested a new drug (KRT-232) combined with three standard myeloma treatments in 35 patients whose cancer had come back or stopped responding. The goal was to find the safest dose and check for side effects. The study was terminated early, so results are limited, but the approach aims to control the disease rather than cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah, 84112, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • NYP/Weill Cornell Medical Center

    New York, New York, 10065, United States

  • UCHealth University of Colorado Hospital

    Aurora, Colorado, 80045, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas, 78229, United States

  • University of Texas at Austin

    Austin, Texas, 78712, United States

Conditions

Explore the condition pages connected to this study.